Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C187689> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- NCIT_C187689 IAO_0000115 "A Fc-engineered fusion protein composed of two human leukocyte antigen (HLA) molecules presenting a Wilms' tumor 1 (WT1) peptide that are each linked to two affinity-attenuated interleukin 2 (IL-2; IL2) molecules, with potential immunomodulating and antineoplastic activities. The HLA molecules presenting a WT1 peptide are peptide-HLA-A*0201 major histocompatibility complex (pMHC) derived from the WT1 peptide encoded by the amino acids 37-45. Upon administration of CUE-102, the pMHC moiety selectively targets, binds to and activates the T cell receptor (TCR) on WT1-specific T-lymphocytes. By selectively delivering the IL-2 moiety to the CD8-positive T-cells, the IL-2 moiety specifically binds to IL-2 receptors on tumor-specific effector T-cells and mediates the selective expansion of WT1-specific T-cells. This increases the T-cell-mediated anti-tumor immune response against WT1-expressing tumor cells and thereby eliminates tumor cells. The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T-cells during a natural immune response. WT1, a co-fetal protein and tumor-associated antigen (TAA), is overexpressed in a number of cancers. The IL-2 variant ('not-alpha' IL-2) preferentially activates tumor-specific CD8+ T-cells and does not prefer to bind to the IL-2 receptor alpha subunit; this minimizes systemic effects on non-tumor-specific T-cells. This minimizes induction of pro-inflammatory cytokines release and non-specific and systemic activation of immune cells." @default.
- NCIT_C187689 NCIT_A7 NCIT_C17549 @default.
- NCIT_C187689 NCIT_NHC0 "C187689" @default.
- NCIT_C187689 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C187689 NCIT_P107 "WT1-targeted IL-2-based Fusion Protein CUE-102" @default.
- NCIT_C187689 NCIT_P108 "WT1-targeted IL-2-based Fusion Protein CUE-102" @default.
- NCIT_C187689 NCIT_P208 "CL1792362" @default.
- NCIT_C187689 NCIT_P322 "CTRP" @default.
- NCIT_C187689 NCIT_P322 "GDC" @default.
- NCIT_C187689 NCIT_P399 "809640" @default.
- NCIT_C187689 normalizedInformationContent "100" @default.
- NCIT_C187689 referenceCount "1" @default.
- NCIT_C187689 hasExactSynonym "CUE 102" @default.
- NCIT_C187689 hasExactSynonym "CUE-102" @default.
- NCIT_C187689 hasExactSynonym "CUE102" @default.
- NCIT_C187689 hasExactSynonym "Fusion Protein CUE-102" @default.
- NCIT_C187689 hasExactSynonym "IL-2-based CUE-102" @default.
- NCIT_C187689 hasExactSynonym "Immuno-STAT CUE-102" @default.
- NCIT_C187689 hasExactSynonym "Selective Targeting and Alteration of T-cells CUE-102" @default.
- NCIT_C187689 hasExactSynonym "WT1-targeted IL-2-based Fusion Protein CUE-102" @default.
- NCIT_C187689 inSubset NCIT_C116977 @default.
- NCIT_C187689 inSubset NCIT_C116978 @default.
- NCIT_C187689 inSubset NCIT_C128784 @default.
- NCIT_C187689 inSubset NCIT_C157711 @default.
- NCIT_C187689 inSubset NCIT_C157712 @default.
- NCIT_C187689 inSubset NCIT_C176424 @default.
- NCIT_C187689 type Class @default.
- NCIT_C187689 isDefinedBy ncit.owl @default.
- NCIT_C187689 label "WT1-targeted IL-2-based Fusion Protein CUE-102" @default.
- NCIT_C187689 subClassOf NCIT_C1512 @default.
- NCIT_C187689 subClassOf NCIT_C187689 @default.
- NCIT_C187689 subClassOf NCIT_C1908 @default.
- NCIT_C187689 subClassOf NCIT_C1909 @default.
- NCIT_C187689 subClassOf NCIT_C307 @default.
- NCIT_C187689 subClassOf NCIT_C308 @default.